Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Abstract Objective Crizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). The objective of this study was to explore the efficacy of crizotinib in advanced non-small-ce...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rui-Lian Chen, Jun Zhao, Xu-Chao Zhang, Na-Na Lou, Hua-Jun Chen, Xue Yang, Jian Su, Zhi Xie, Qing Zhou, Hai-Yan Tu, Wen-Zhao Zhong, Hong-Hong Yan, Wei-Bang Guo, Yi-Long Wu, Jin-Ji Yang
Formato: Artigo
Lenguaje:Inglês
Publicado: BMC 2018-11-01
Colección:BMC Cancer
Materias:
Anaplastic lymphoma kinase
Mesenchymal epithelial transition
Non-small-cell lung cancer
Rearrangement
C-Met, overexpression
Acceso en línea:http://link.springer.com/article/10.1186/s12885-018-5078-y
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares